CN Patent

CN113164515A — 用混合金属化合物治疗的方法

Assigned to Elgin Pharmaceutical Co ltd · Expires 2021-07-23 · 5y expired

What this patent protects

一种治疗和/或预防血管钙化的方法可以包含向有需要的受试者施用混合金属化合物。

USPTO Abstract

一种治疗和/或预防血管钙化的方法可以包含向有需要的受试者施用混合金属化合物。

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: CN113164515A
Jurisdiction: CN
Classification: —
Expires: 2021-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Elgin Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.